Nivolumab in combination with CIMAvax-EGF for lung cancer
Dr Grace Dy - Roswell Park Cancer Institute, USA
Nivolumab in combination with CIMAvax-EGF for lung cancer ( Dr Grace Dy - Roswell Park Cancer Institute, USA )
4 Jan 2019
Large food and alcohol companies are undermining public health
Prof Rob Moodie, Melbourne School of Population and Global Health, Malawi Colleg...
Large food and alcohol companies are undermining public health ( Prof Rob Moodie, Melbourne School of Population and Global Health, Malawi College of Medicine )
6 Nov 2018
Alcohol consumption and cognitive dissonance in the west
Prof Terry Slevin, Public Health Association of Australia
Alcohol consumption and cognitive dissonance in the west ( Prof Terry Slevin, Public Health Association of Australia )
6 Nov 2018
Using genetics to close the knowledge gap on cancer causation
Dr Paul Brennan, International Agency for Research On Cancer (IARC) (France
Using genetics to close the knowledge gap on cancer causation ( Dr Paul Brennan, International Agency for Research On Cancer (IARC) (France )
6 Nov 2018
The IMpower-132 trial for non small cell lung cancer
Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center...
The IMpower-132 trial for non small cell lung cancer ( Dr Vassiliki Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, US )
29 Oct 2018
Current clinical landscape for ALK non-small cell lung cancer patients
Dr Riyaz Shah and Dr Maurice Perol
Current clinical landscape for ALK  non-small cell lung cancer patients ( Dr Riyaz Shah and Dr Maurice Perol )
26 Oct 2018
Latest advances in treatment for ALK positive NSCLC
Prof Gordon McVie, Dr Lázaro Quintela
Latest advances in treatment for ALK positive NSCLC ( Prof Gordon McVie,  Dr Lázaro Quintela )
26 Oct 2018
Highlights in early non-metastatic NSCLC and thoracic tumours
Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain
Highlights in early non-metastatic NSCLC and thoracic tumours ( Dr Enriqueta Felip - Vall d'Hebron University Hospital (VHIO), Barcelona, Spain )
26 Oct 2018
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with ...
Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montp...
Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC ( Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France )
26 Oct 2018
Highlights in SCLC from ESMO 2018
Dr Noemi Reguart - University of Barcelona, Barcelona, Spain
Highlights in SCLC from ESMO 2018 ( Dr Noemi Reguart - University of Barcelona, Barcelona, Spain )
26 Oct 2018
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel ...
Dr David R. Spigel - Tennessee Oncology, Nashville, USA
ABOUND.sqm: nab-paclitaxel and carboplatin induction followed by nab-paclitaxel maintenance in NSCLC ( Dr David R. Spigel - Tennessee Oncology, Nashville, USA )
26 Oct 2018
ASCEND-8: safety data of ceritinib with or without food in NSCLC
Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea
ASCEND-8: safety data of ceritinib with or without food in NSCLC ( Prof Byoung Chul Cho - Yonsei Cancer Center, Seoul, Republic of Korea )
26 Oct 2018